## Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## budesonide-glycopyrrolate-formoterol (Breztri Aerosphere)

## Notes:

- Quantity Limits: No
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- <sup>^</sup> Adequate trial is defined as at least 30 days treatment duration

<u>Initiation (new start) criteria</u>: Non-formulary **budesonide-glycopyrrolate-formoterol** (**Breztri Aerosphere**) will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is an Pulmonologist
- Patient is at least 18 years of age
- Patient has diagnosis of chronic obstructive pulmonary disease (COPD)
- History of failure, contraindication, or intolerance\* to treatment with an adequate trial<sup>^</sup>
  of a triple therapy regimen containing an inhaled corticosteroid (ICS), a long acting
  anti-cholinergic (LAMA), and a long acting beta-agonist (LABA) from separate devices.
- Documented clinical rationale that the patient is unable to separate inhaler products.

Examples of a triple therapy ICS+LAMA+LABA regimen using multiple inhaler devices (list is not inclusive of all possible triple therapy combinations):

Inhaler #1	Inhaler #2
Fluticasone propionate/salmeterol	Tiotropium
(Wixela Inhub, Advair Diskus, Advair HFA)	(Spiriva Respimat, Spiriva HandiHaler)
Budesonide/formoterol	Tiotropium
(Symbicort)	(Spiriva Respimat, Spiriva HandiHaler)
Tiotropium/olodaterol	ciclesonide (Alvesco)
(Stiolto Respimat)	fluticasone propionate (Flovent)

kp.org

Revised: 05/13/21 Effective: 07/15/21 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



## Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

budesonide-glycopyrrolate-formoterol (Breztri Aerosphere)

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary **budesonide-**<u>glycopyrrolate-formoterol</u> (Breztri Aerosphere) will be covered on the prescription drug benefit when the following criteria are met:


- Patient is at least 18 years of age
- Patient has diagnosis of chronic obstructive pulmonary disease (COPD)
- History of failure, contraindication, or intolerance\* to treatment with an adequate trial<sup>^</sup>
  of a triple therapy regimen containing an inhaled corticosteroid (ICS), a long acting
  anti-cholinergic (LAMA), and a long acting beta-agonist (LABA) from separate devices.

Examples of a triple therapy ICS+LAMA+LABA regimen using multiple inhaler devices (list is not inclusive of all possible triple therapy combinations):

Inhaler #1	Inhaler #2
Fluticasone propionate/salmeterol	Tiotropium
(Wixela Inhub, Advair Diskus, Advair HFA)	(Spiriva Respimat, Spiriva HandiHaler)
Budesonide/formoterol	Tiotropium
(Symbicort)	(Spiriva Respimat, Spiriva HandiHaler)
Tiotropium/olodaterol	Ciclesonide (Alvesco)
(Stiolto Respimat)	fluticasone propionate (Flovent)

kp.org

Revised: 05/13/21 Effective: 07/15/21





All plans offered and underwritten by